Delante, Mayline .
HRN: 11-29-27 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/18/2022
CEFUROXIME 500MG (TAB)
11/18/2022
11/25/2022
ORAL
500mg/tab
BID
S/P NSVD; THICKLY MSAF
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes